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ST waveform analysis is purposed to be better for labor surveillance than conventional CTG. 
We quantified the efficacy of these two methods, assessing quality of the scientific evidence 
with the GRADE tool, and determined that evidence is insufficient to justify the use of ST 
waveform analysis as intrapartum monitoring.  
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Introduction. ST waveform analysis (STAN) was introduced to reduce metabolic acidosis at 
birth and avoid unnecessary operative deliveries relative to conventional cardiotocography 
(CTG). Our objective was to quantify the efficacy of STAN vs. CTG and assess the quality of 
the evidence by using the GRADE tool. Material and Methods. We identified randomized 
controlled trials (RCTs) through systematic literature searches and assessed included studies 
for risk of bias. Meta-analyses were performed, calculating pooled risk ratio (RR) or peto 
odds ratio (OR). We performed post hoc trial sequential analyses for selected outcomes to 
assess the risk of false-positive results and the need for additional studies. Results. Six RCTs 
were included in the meta-analysis. STAN was not associated with a reduction in operative 
deliveries due to fetal distress, but we observed a significantly lower rate of metabolic 
acidosis (peto OR 0.64; 95% confidence interval [CI] 0.46–0.88). Accordingly, 401 women 
need to be monitored with STAN to prevent one case of metabolic acidosis. No statistically 
significant effects were observed in other fetal or neonatal outcomes, except from fetal blood 
sampling (RR 0.59; 95% CI 0.45–0.79) and a minor reduction in the number of operative 
vaginal deliveries for all indications (RR 0.92; 95% CI 0.86–0.99). The quality of the 
evidence was high to moderate. Conclusions. Absolute effects of STAN were minor, and the 
clinical significance of the observed reduction in metabolic acidosis is questioned. There is 





Fetal monitoring should identify fetuses at risk of neonatal and long-term injury attributable to 
asphyxia. The aim is to identify and timely intervene in preventable cases of fetal damage.  
 
Cardiotocography (CTG) was introduced in the 1960s and assumed to prevent fetal asphyxia. 
The CTG method has low specificity and high false-positive rates; therefore, its introduction 
into clinical practice was associated with increased incidences of cesarean section and 
operative vaginal delivery (1). Hence, a test with higher diagnostic accuracy is needed to 
identify truly hypoxic fetuses.  
 
The ST waveform analysis (STAN) method was introduced after extensive experimental 
research (2). A lack of fetal oxygen produces changes in the fetal ECG waveform analysis. 
The method can be used after rupture of membranes in single pregnancies after 36 weeks’ 
gestation, and it is purported that the STAN method (i.e., cardiotocography plus fetal STAN) 
can reduce metabolic acidosis at birth and avoid unnecessary operative deliveries (2).  
 
Randomized controlled trials (RCTs) are designed to measure the efficacy of interventions 
and allow causal inferences between treatments and outcomes. By 2015, more than 15 000 
women in labor had been randomized to receive either the STAN method or conventional 
CTG alone in attempts to estimate the efficacy of the STAN method (3-7). All five RCTs 
were performed in Europe, but they reported different outcomes and conflicting evidence. 
Five previous systematic reviews and one review article have compared STAN with CTG 
alone in meta-analyses (8-13). Three of the meta-analyses included all five RCTs (8, 9, 12); 
two (10, 11) excluded the Westgate trial (3) and one (13) excluded the Vayssière trial (6). A 
meta-analysis from 2012 showed no difference in perinatal outcomes between STAN and 
CTG alone, except a reduction in operative vaginal deliveries (8), whereas a second meta-
analysis from 2012 reported a reduction in the need for fetal blood sampling and operative 
vaginal deliveries (9). Three systematic reviews (10-12) from 2013 all reported a reduction in 
the need for fetal blood sampling; additionally, two found reductions in operative vaginal 
deliveries (11, 13), and one reported a reduction in transfers to the neonatal intensive care unit 
(12). The most recent meta-analysis published in 2014 reported significantly reduced rates of 





Recently, a large multicenter study from the United States including 11 108 patients showed 
that fetal ECG ST-segment analysis as an adjunct to conventional intrapartum electronic fetal 
monitoring neither improved perinatal outcomes nor decreased operative delivery rates (14). 
Because a new large trial has been published, and also because previous meta-analyses had 
different conclusions, a new systematic review to compare the effects of STAN vs. CTG 
alone (15) is warranted. 
 
The aim of this review is to quantify the efficacy of the STAN method as an adjunct to 
conventional CTG compared with CTG alone. In addition to conventional quality assessments 
, we used the Grading of Recommendations Assessment, Development and Evaluation 
(GRADE) to assess the overall quality of evidence (16) and trial sequential analyses (TSA) to 
clarify the need for additional trials (17).            
 
Material and methods 
 
This systematic review was conducted based on a protocol published in the PROSPERO 
international prospective register of systematic reviews, registration no. CRD42015023563. 
We did some minor deviations from the protocol (Supplementary file S1). No ethical approval 
was needed. 
 
We developed a search strategy, and a systematic literature search was performed in the 
following databases: Ovid MEDLINE® (In-Process & Other Non-Indexed Citations, Ovid 
MEDLINE®, Daily, Ovid MEDLINE® and Ovid OLDMEDLINE® 1946 to Present), 
EMBASE Classic+ (EMBASE 1947 to 2015 September 16) (Ovid), The Web of Science® 
(Thomson Reuters), Scopus® (Elsevier), The Cochrane Library (Wiley), and CINAHL Plus 
(EBSCOhost). 
 
An initial search, with the search terms and combinations shown in Supplementary file S2, 
was performed in May 2015. This search was followed up by a repetitive search in September 
2015 (Supplementary file S2). The controlled vocabulary of Medical Subject Headings 
(MeSH) from MEDLINE, and the Emtree thesaurus from EMBASE, including sub-headings, 
were used when applicable. In addition, the search fields title, abstract, and keywords, were 
searched. In The Web of Science, the search fields title and topic were used. All references 
5 
 
were exported to Endnote™ (x7.4 – Thompson Reuters), where duplicates were removed. 
There were no restrictions regarding languages or publication year.  
 
Study selection and data extraction procedures 
First, the citations identified by the electronic searches were screened and potentially eligible 
studies were obtained in full text for further assessment. Two reviewers (EB and LMR) 
independently assessed eligibility of the studies. Persisting disagreements were resolved by 
consulting a third reviewer (PØ). The selection criteria were as follows:  
 Population: Women in labor, > 36 weeks of gestation with a singleton fetus in a 
cephalic presentation and a decision for continuous electronic fetal monitoring during 
labor; 
 Intervention: CTG plus STAN; 
 Comparator: CTG alone; 
 Primary outcomes: Operative deliveries for fetal distress, metabolic acidosis in the 
newborn (pH <7.05 and BD(ecf) >12 mmol/L in umbilical artery). Secondary outcomes: 
neonatal and perinatal death, neonatal seizures, neonatal encephalopathy, transfers to 
the neonatal intensive care unit (NICU), fetal blood sampling, cesarean sections, 
operative vaginal delivery, Apgar score  <7 at 5 min and a composite (i.e., either 
intrapartum death, neonatal death, Apgar score <4 at 5 min, neonatal seizures, 
metabolic acidosis, intubation at delivery for ventilation or neonatal encephalopathy); 
 Study design: RCT.   
 
Two of the reviewers (EB and LMR) extracted data from each study using a predesigned 
form. 
 
Assessments and synthesis 
All studies meeting the selection criteria were critically appraised using the Risk of Bias tool 
developed and recommended by the Cochrane Collaboration (18). Two reviewers (EB and 
LMR) performed the risk of bias assessments independently. Persisting disagreements were 
resolved by consulting a third reviewer (KGB). 
 
Numbers of mothers or infants with the outcome of interest were extracted from all included 
studies. Outcomes occurring relatively frequently were analyzed by calculating the pooled 
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risk ratio (RR) with 95% confidence interval (CI) in accordance with a random-effect model. 
Rare outcomes with incidence less than 1% were combined using peto odds ratio and a fixed-
effect model (19). All computations were performed using Review Manager (RevMan, 
Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014). 
Forest plots intended for publications were prepared using R software (Version3.1.2, Vienna: 
R Foundation for Statistical Computing, 2014) and the forest plot package (20, 21). 
 
To assess the risk of random errors and false-positive results, and to help clarify the need for 
additional trials by calculating an optimal information size (17), we performed post hoc TSA 
for selected outcomes in TSA viewer (Version 0.9 beta. Copenhagen: Copenhagen Trial Unit, 
2011). 
 
We did not perform any subgroup analysis, but conducted sensitivity analysis where we 
excluded one trial using old STAN technology (3), and one trial that used a different 
algorithm for interventions (14). Separate analyses were prepared to explore the impact of 
pooling data on neonatal and perinatal deaths. 
 
We present overall assessment of the quality of evidence in a “summary of findings” table. 
The assessment includes the magnitude of effect of the STAN method vs. CTG alone, and a 
summary of available data on the most important outcomes (22). The quality of evidence was 
judged as either high, moderate, low, or very low (23).  
 
Results 
The electronic searches identified 921 unique records (Fig. 1) and one was identified by 
personal field knowledge. Ten records were assessed in full text; one was excluded because it 
evaluated the effect of CTG plus fetal ECG PR analyses, not ST analyses (24). The other nine 
records were included, six were original studies (3-7, 14) and three contributed additional data 
and corrections to already published studies (25-27).  
 
Description of included studies 
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The included studies were performed in Sweden (4), USA (14), Finland (5), France (6), the 
Netherlands (7), and the UK (3) and included 26 554 women and their babies (Table 1). Most 
trials used the STAN S21 or S31 monitors (Neoventa AB), whereas the Westgate trial (3) 
used an older device without computerized assessment for the fetal ECG (STAN 8801, 
Cinventa AB). The Westgate study included women from 34 weeks gestation. We performed 
sensitivity analyses without the Westgate study. Moreover, the decision algorithm used in the 
Belfort study (14) implied that the fetal heart rate status was classified into three zones (green, 
red, yellow), which correspond closely to the 2008 National Institute of Child and Human 
Development criteria (28). If the fetal heart rate pattern is in the yellow zone, intervention is 
recommended if any ST event (either episodic or baseline increase) or two biphasic ST events 
occur. As this algorithm is different from the one used in other studies, we also conducted 
sensitivity analysis without the Belfort study. 
 
We assessed the overall risk of bias as low in all the included trials (Table 1, Supplementary 
file S3).  
 
The effect of STAN method vs. CTG alone 
The six available trials included 26 554 women in labor, but a minority of the investigated 
outcomes reached statistical significance (Table 2, Supplementary file S4). Some of the 
investigated outcomes are rare, with incidence much lower than one percent, and it is difficult 
to gain statistical power for definite conclusions. Lack of power was not an issue for the 
investigated maternal outcomes, and our meta-analysis showed that the use of the STAN 
method is associated with little or no difference in the rate of cesarean sections (RR 0.93; 95% 
CI 0.78–1.12) or operative vaginal deliveries (RR 0.87; 95% CI 0.74–1.03) for fetal distress 
(Table 3). Conversion to absolute numbers suggests that the STAN method would probably 
result in five more to 10 fewer cesarean sections induced by fetal distress, and between two 
more and 14 fewer operative vaginal deliveries per 1000 cases of labor (Table 3). 
 
Metabolic acidosis occurred with an incidence less than one percent in the group receiving 
CTG alone, and even lower in the STAN group (OR 0.64; 95% CI 0.46–0.88; Table 3). The 
difference corresponds to a number needed to treat to benefit of 401 (95% CI 232–1457), 
which means that one case of neonatal metabolic acidosis is avoided for every 401 women 
monitored with STAN. Given a higher baseline incidence of metabolic acidosis, e.g. 1.4% as 
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in the Amer-Wahlin trial (4), the NNT decreases to 198. All included trials reported data on 
deaths and three reported neonatal seizures (Fig. 2). Neither resulted in statistically significant 
differences between the STAN method vs. CTG alone: OR of 1.79 (95% CI 0.69–4.64) and 
0.58 (95% CI 0.18–1.90), respectively. The CIs were wide when expressed in relative terms, 
but re-expressed in absolute terms they imply that STAN can be associated with one fewer to 
17 more deaths per 10 000 births, and between nine fewer and nine more neonatal seizures per 
10 000 births. Apgar scores <4 after 5 min seemed to occur more frequently with STAN (OR 
2.63; 95% CI 1.16–5.96), but we found little or no difference with regard to the incidence of 
newborns with Apgar scores <7 after 5 min (RR 0.95; 95% CI 0.73–1.25; Table 3 and Fig. 2).    
 
Of the other investigated maternal outcomes, only operative vaginal delivery for all 
indications reached statistical significance. The effect size suggests that the clinical relevance 
of the differences is limited (Table 2). Similarly, the other investigated neonatal outcomes 
pointed towards little or no difference between STAN vs. CTG alone. The only exception to 
this pattern was fetal blood sampling, which occurred less frequently in the STAN group. The 
magnitude of this effect was inconsistent across the available trials (Table 2, Supplementary 
file S4).   
 
Sensitivity analysis 
Analyses shows that the results are robust with regard to inclusion or exclusion of the 
Westgate (3) or Belfort (14) trials (Supplementary file S4). Because we decided to pool 
studies reporting neonatal and perinatal deaths, we also conducted a sensitivity analysis to 
explore the possible impact of this decision. The results were consistent among the studies 
reporting neonatal deaths (Supplementary file S4). 
 
Trial sequential analysis 
We determined that a relative risk reduction of 20% represent a clinically important difference 
in the number of operative deliveries for fetal distress (cesarean sections, vacuum or forceps). 
In this case, the TSA estimated the optimal information size at 29 940 participants, but 
suggested that the available sample size was sufficient to conclude that the two treatments are 
non-inferior (Supplementary file S5). Furthermore, as the majority of newborns with 
metabolic acidosis are without symptoms or elevated risk for adverse outcomes (29), we held 
50% relative risk reduction as clinically important. The main analysis indicated that there was 
a statistically significant difference between STAN and CTG alone (Supplementary file S5), 
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but the conclusion depended on the choice of statistical methods. The significance was lost 
when we used peto OR in combination with a random-effect model rather than in combination 
with a fixed-effect model. With regard to perinatal- and neonatal deaths and neonatal seizures, 
the results were far from statistically significant, but the number of observed events was too 
small to allow firm conclusions about superiority or non-inferiority. For Apgar score <7 after 
5 min, TSA showed signs of non-inferiority, i.e., no important difference between the groups.  
 
Summary of findings 
The application of GRADE showed that the quality of evidence was moderate or high for the 




With regard to our primary outcomes, the STAN method did not lead to a reduction in 
operative deliveries due to fetal distress, but was associated with a reduction in metabolic 
acidosis. 
 
The meta-analysis showed no significant difference in perinatal or neonatal deaths, seizures, 
neonatal encephalopathy, pH < 7.05 in cord artery, Apgar score < 7 after 5 min, neonatal 
intubation, or transfers to the NICU. There was no difference in total operative delivery rate, 
but a small significant reduction in operative vaginal deliveries for all indications. We found a 
statistically significant reduction in fetal blood sampling in the STAN group. 
 
Our review has several strengths. Our findings are based on a thorough and up-to-date 
literature search . We included a recently published trial and used corrected data from earlier 
trials. All trials are associated with a low risk of bias, and our findings seem robust with 
regard to inclusion or exclusion of two trials that prompted external validity. Other strengths 
are our application of GRADE to judge the quality of the evidence and the use of TSA to 
estimate statistical power and optimal information sizes for different outcomes. Even though 
GRADE and TSA can be seen as methodological strengths, it is important to note that both 
methods are based on subjective evaluations, and hence, some disagreement among readers is 
to be expected. Only RCTs were included in this systematic review. Some relevant outcomes 
occur at very low incidences, and it is possible that the inclusion of well-designed 




RCTs are considered the gold standard for clinical trials. They are typically conducted in ideal 
conditions and under the supervision of dedicated experts. Thus, the external validity to a 
normal clinical setting, i.e., the distinction between efficacy and effectiveness, can be 
questioned. The setting is almost never identical across all trials, and this is also the case for 
the six STAN trials. We believe the observed variation in settings is as can be expected to 
normal variation in practice, and therefore we decided to include all six trials in our meta-
analysis. We are aware that the appropriateness of including some of the trials has been 
discussed (8-13, 30-33), and we therefore conducted sensitivity analyses to explore the 
robustness of our results. The overall conclusions of this review are robust with regard to the 
inclusion or exclusion of the oldest study that used non-computerized ST analysis (3) and the 
newest that used another decision algorithm (14).  
 
The STAN method is widely used in Scandinavia and some other European countries. Earlier 
systematic reviews did not unequivocally recommend the technique (8-12), and the results 
from the Belfort study were eagerly awaited. However, this study used different decision 
algorithms from those of previous European trials, and the appropriateness of pooling can be 
debated. Importantly, the algorithms used by Belfort and coworkers were those recommended 
by the company that produces the STAN technology (Neoventa Medical AB) for their Food 
and Drug Administration approval and the ones that have been certified for use in the United 
States. The decision to change the algorithm was made by Neoventa and not the study 
investigators (personal communication, Michael Belfort, October 24th, 2015).      
 
The included trials report numerous outcomes. We argue that the most important of these are 
perinatal and neonatal death, neonatal encephalopathy, seizures, and neurologic sequelae such 
as cerebral palsy was not reported since a long follow-up period is needed. Outcomes such as 
Apgar score < 7/5 min, transfers to NICU, and intubation for ventilation are less important. 
From a methodological perspective, it is interesting to note that all relevant neonatal outcomes 
occur with extremely low incidence (for example, less than 0.1% for death and 0.7% for 
metabolic acidosis). Under these circumstances, there is a risk that the use of relative effect 
sizes such as odds ratios inflates the reader’s perception of the magnitude of a possible effect 
(34). Misconception can be avoided by presenting the relative effect sizes together with the 




The rate of metabolic acidosis was significantly reduced, but there was a non-significant 
increase in the death rate in the STAN group. This finding may be the result of chance or a 
real effect. One theory could be that the STAN technology signals problems at a late stage of 
compensation, and deterioration is so rapid afterwards that that an intervention may not occur 
quickly enough in some cases. 
 
Metabolic acidosis has long been viewed as a crucial outcome, but we regard it as a surrogate 
endpoint. It has been argued that surrogate outcomes with a higher incidence are necessary for 
efficient evaluation of intrapartum monitoring because the numbers of events for well-defined 
hard outcomes (such as death) are small (9). Methodological research has shown that 
surrogate endpoints are frequently associated with biased results (35). The appropriate use of 
surrogate endpoints requires accurate knowledge and direct correlation between the surrogate 
and the truly important outcome, and we argue that the relationship between metabolic 
acidosis and harder outcomes is questionable.  
 
First, there is a known relationship between low cord artery pH values and serious outcome, 
but the threshold remains unknown (36). Few neonates with severe acidemia appear to have 
sequelae, and most neonates with adverse outcomes—even those with seizures—are not born 
acidemic. A study analyzing umbilical artery pH and serious neonatal outcomes in more than 
50 000 validated samples from electronically monitored laboring women, showed that 2.2 % 
of the neonates had a cord pH < 7.00, and only 0.22 % had neonatal encephalopathy (grade 2–
3). Only 22 % of all cases with encephalopathy and seizures or death had a pH < 7.00 (37). 
Another study from the same group showed that an arterial pH < 7.00 significantly predicted 
neonatal outcomes (38), but the addition of BD(ecf) did not improve the prediction. It is also 
important to know that similar cord gases may have very different outcomes. The relationship 
between cord pH values of 7.00–7.10 is much less clear (38).  
 
Second, a Swedish study (29) showed that among 14 687 deliveries, 78 infants (0.5 %) had 
metabolic acidosis, but 45 % of these infants appeared healthy at birth and did not require 
transfer to the NICU. This group had no increased risk for neurologic or behavioral problems 
compared with control children at the age of 6.5 years. 
 
Third, about 75 % of neonates with encephalopathy with seizures or death are born with a pH 
> 7.00. This may be owing to the “acidosis paradox,” where neonates without acidemia might 
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be hypoxic but unable to develop acidemia as a response (37, 39). However, the causes of 
severe long-term neurologic sequelae are probably more complex than previously believed 
and not simply due to hypoxia with metabolic acidosis (40). Thus, it seems obvious that 
metabolic acidosis is a surrogate endpoint, and should be interpreted with caution. We found a 
statistically significant difference in favor of STAN when comparing the incidence of 
metabolic acidosis, without observing similar effects in other important outcomes. We 
therefore discourage excessive emphasis on the positive results for metabolic acidosis. 
 
In addition to conventional meta-analysis, we conducted TSA on selected endpoints to 
explore the possible impact of random errors and false-positive results on the conclusions of 
our meta-analysis. TSA can allow power analysis to clarify the need for additional trials (17). 
These analyses showed that the statistical power is too low to draw firm conclusions about 
superiority or non-inferiority of either STAN or CTG alone on deaths or neonatal seizures. In 
contrast, TSA showed adequate statistical power to conclude that the STAN method is 
probably not associated with important reductions in Apgar < 7 at 5 min or with operative 
deliveries for fetal distress. 
 
Metabolic acidosis was associated with a statistically significant improvement in favor of 
STAN in the main analysis. Our protocol stated that this analysis should be performed using a 
random-effect model, but as RevMan does not enable the use of a random-effect model in 
combination with peto OR effect sizes, the main analysis was based on a fixed-effect model. 
Interestingly, the TSA analysis showed that the significant finding for metabolic acidosis 
disappeared in meta-analysis based on random-effect models, a result that underpins the need 
for caution in interpreting the statistically significant finding for metabolic acidosis. 
 
Our meta-analysis includes the recent US study (14), and shows that the STAN technology 
does not reduce important outcomes such as perinatal or neonatal death, neonatal 
encephalopathy, seizures, or total operative delivery rate for fetal distress, but does reduce the 
fetal blood sampling and metabolic acidosis rates. A recent review of observational studies, 
reported similar outcomes (41). The reduction in fetal blood sampling is expected, as it is one 
main reason for introducing the STAN technology, although fetal blood sampling was 
optional in most of the RCTs. By applying GRADE, we assessed the quality of evidence for 
all important outcomes as either moderate or high, which implies that our results are close to 




There is no clear indication that STAN causes harm. Some hospitals using STAN may 
therefore choose to continue, while others may not. In our opinion, hospitals not using STAN 
should not introduce it, as evidence for benefit is too scarce. 
 
To date, more than 26 000 women and their babies have been included in RCTs to assess the 
effects of STAN compared with CTG alone. A modest reduction in the rate of metabolic 
acidosis has been reported, but no reduction in severe neonatal morbidity, mortality rates, or 
operative delivery rates for fetal distress. To conclude whether STAN performs better than 
CTG alone in reducing the rate of neonatal seizures, another 50 000 women need to be 
included in RCTs. For conclusions regarding perinatal or neonatal death, a minimum of 90 
000 more women and their babies need to be included. The benefits or harms found will 
probably be marginal. It is time to conclude that STAN is not better than CTG alone. 
 
There was no specific funding for this study. 
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Table 1. Characteristics of included studies 
 
Paper Amer-Wåhlin, Sweden (4, 25) Belfort, USA (14) Ojala, Finland (5) Vayssière, France (6) Westerhuis, The Netherlands (7, 26) Westgate, UK (3) 
Type of study 
 
Multicenter (3 centers) Multicenter (16 centers) Single center Multicenter (2 centers) Multicenter (9 Centers) Single center 
No. included 5049 (revised ITT-analyses) 11 108 1483 799 5681 2434 
Inclusion criteria Women in active labor > 36 
gestational w, with singleton 
fetuses in a cephalic presentation 
and where a clinical decision of 
continuous internal CTG 
Women with a singleton fetus at more 
than 36 w of gestation who were 
attempting vaginal delivery and had 
cervical dilation of 2 to 7 cm 
Consecutive women in active labor with 
term (>36+0 gestational w) pregnancy, 
with a singleton fetus in a cephalic 
presentation and a decision about 
amniotomy 
Women in labor with a term (> 36 
gestational w) singleton fetus in cephalic 
presentation who met the following 
inclusion criteria: abnormal CTG or thick 
meconium-stained amniotic fluid 
Laboring women aged 18 y or older 
with a singleton high-risk 
pregnancy, a fetus in cephalic 
presentation, gestational age >36 
w, and an indication for internal 
electronic monitoring 
All pregnancies of >34 w gestation 
with no gross fetal abnormality and 
with a decision to apply a scalp 
electrode 
Exclusion criteria  Noncephalic presentation, planned 
CS, a need for immediate delivery, 
absent fetal heart-rate variability or a 
sinusoidal pattern, minimal fetal 
heart-rate variability in the 20 
minutes before randomization, or 
other fetal or maternal conditions that 
would preclude a trial of labor or the 
placement of a scalp electrode 
Contraindications for scalp electrode or 
admitted to the labor ward in the 
second phase of labor 
Gestational age <36 w , normal CTG 
during labor, maternal infection 
contraindicating placement of scalp 
electrodes (seropositive for HIV or 
hepatitis B or C) cardiac  malformation, 
severe decelerations with variability 
reduced immediately on entry into the 
delivery room 
  
Intervention STAN S21 (Neoventa AB) STAN S31 (Neoventa AB) STAN S21 (Neoventa AB) STAN S21 (Neoventa AB) 
 
STAN S21 or S31 (Neoventa AB) STAN 8801 (Cinventa AB) 
Algorithm for 
interventions in STAN 
group 
 
Table 1, Amer-Wåhlin (4) Supplementary appendices and trial 
protocol, referred to in Belfort (14) 
As Amer-Wåhlin (4) As Amer-Wåhlin (4) FIGO guidelines and STAN clinical 
guidelines, see appendices 1 & 2, 
referred to in  Westerhuis (7) 
Tables 1 & 2, Westgate (3) 
Control 
 
Masked STAN S21 Masked STAN S31 CTG (Hewlett-Packard 8030A CTG (Hewlett-Packard 8030A Conventional FHR monitor  CTG (Hewlett-Packard 8040A) 
Proportion primiparas 62% in both arms1 42.6% in both arms 51.0% in CTG+STAN arm, 52.4% in CTG 
arm 
72.2% in CTG+STAN arm, 71.8% in CTG 
arm 
 
57.2% in CTG+STAN arm, 57.0% in 
CTG arm 
- 
Previous CS - - - 6.3% in CTG+STAN arm, 6.0% in CTG arm 
 
12.2% in CTG+STAN arm, 13.1% in 
CTG arm 
- 
Induction of labor 17% in both arms1 59.2% in CTG+STAN arm, 58.6 % in 
CTG arm 
20.0% in CTG+STAN arm, 17.5% in CTG 
arm 
8.5% in CTG+STAN arm, 8.8% in CTG arm 
 





37% in CTG+STAN arm, 40 % in 
CTG arm* 
- 54.6% in CTG+STAN arm, 54.0% in CTG 
arm 
91.2% in CTG+STAN arm, 90.3% in CTG 
arm 




Overall risk of bias2 
 
Low risk of bias 
 
Low risk of bias 
 
Low risk of bias 
 
Low risk of bias 
 
Low risk of bias 
 
Low risk of bias 
 
1Originally, 5049 women were included and randomized to the study. 83 were excluded for technical reasons, leaving 4966 women for the analyses. In 2011 (24) the authors published analyses according to intention 
to treat including the 83 previous excluded cases. The estimates are based on the publication from 2001 (4).  
2See Supplemetary file S3 for detailed risk of bias assessment. 
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Table 2. Outcome events and meta-analyses 
Outcome No. of 
studies 
Events, n/N Effect 
measure1 




Metabolic acidosis 6 151/26493 Peto OR 0.64 (0.46-0.88) 31 
Total operative deliveries2 for fetal distress 6 2514/26446 RR 0.88 (0.75-1.03) 74 
Perinatal and neonatal deaths 6 17/26446 Peto OR 1.79 (0.69-4.64) 0 
Neonatal seizures 3 11/13343 Peto OR 0.58 (0.18-1.90) 0 
Apgar  <4 at 5 min  1 23/11108 Peto OR 2.63 (1.16-5.96) - 
Apgar <7 at 5 min 5 211/15303 RR 0.95 (0.73-1.25) 0 
Neonatal encephalopathy 4 25/23177 Peto OR 0.66 (0.30-1.46) 14 
Neonatal intubation 2 85/12544 Peto OR 1.37 (0.90-2.10) 34 
Fetal blood sampling 5 2103/15338 RR 0.59 (0.45-0.79) 91 
Admittance to NICU 5 1521/26410 RR 1.00 (0.90-1.11) 0 
Cord pH <7.05 4 216/10336 RR 1.05 (0.63-1.76) 66 
Composite endpoint3 1 92/11108 Peto OR 1.31 (0.87-1.98) - 
Total operative deliveries2 for all indications 6 6451/26446 RR 0.96 (0.91-1.02) 39 
Cesarean delivery for fetal distress 6 1124/26446 RR 0.93 (0.78-1.12) 47 
Cesarean delivery for all indications 6 3589/26446 RR 1.02 (0.96-1.08) 0 
Assisted vaginal delivery for fetal distress 6 1390/26446 RR 0.87 (0.74-1.03) 59 
Assisted vaginal delivery for all indications 6 2862/26446 RR 0.92 (0.86-0.99) 0 
1 Peto odds ratio (OR) for outcomes with incidence less than 1%, else risk ratio (RR). 
2Total operative deliveries = cesarean sections + assisted vaginal deliveries 
3Composite of intrapartum death, neonatal death, Apgar < 4 at 5 minutes, neonatal seizures, metabolic acidosis, 
























Outcomes Anticipated absolute effects1 
(95% CI)  
Relative effect 
(95% CI)  
№ of participants  
(studies)  
Quality of the 
evidence 
(GRADE)  
Risk with CTG 
alone 
Risk with STAN 
Metabolic acidosis 
Cord pH<7.05 + BD(ecf)>12 mmol/L 
7 per 1000  
4 per 1000 
(3 to 6)  
OR 0.64 
(0.46 to 0.88)  
26493 
(6 RCTs)  
⨁⨁⨁◯ 
MODERATE  3,4 
Cesarean delivery for fetal distress 44 per 1000  
40 per 1000 
(34 to 49)  
RR 0.93 
(0.78 to 1.12)  
26446 
(6 RCTs)  
⨁⨁⨁⨁ 
HIGH  2 
Operative vaginal delivery for fetal 
distress 
55 per 1000  
47 per 1000 
(40 to 56)  
RR 0.87 
(0.74 to 1.03)  
26446 
(6 RCTs)  
⨁⨁⨁⨁ 
HIGH  2 
Neonatal and perinatal death 0 per 1000  
1 per 1000 
(0 to 2)  
OR 1.79 
(0.69 to 4.64)  
26446 
(6 RCTs)  
⨁⨁⨁◯ 
MODERATE  5 
Neonatal seizures 1 per 1000  
1 per 1000 
(0 to 2)  
OR 0.58 
(0.18 to 1.90)  
13343 
(3 RCTs)  
⨁⨁⨁◯ 
MODERATE  5 
Apgar score <7 at 5 min 14 per 1000  
13 per 1000 
(10 to 18)  
RR 0.95 
(0.73 to 1.25)  
15303 
(5 RCTs)  
⨁⨁⨁◯ 
MODERATE  6 
1. Calculations based on mean incidence in study populations 
2. OIS achieved. RRR probably less than 20% 
3. A surrogate estimate with questionable clinical importance. Choose not to downgrade 
4. Both estimate and the conclusion of TSA unstable with regard to choice of analytic methods (e.g fixed vs random model) 
5. Current information size much lower than OIS for detecting a 50% reduction with 80% certainty 
6. Wide confidence interval – imprecise data 
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Supplementary file S1. Deviations from the protocol 
1. In the protocol, we wrote: “One person will extract data from included studies by using a 
data extraction form. Another person will check the data extraction.” When performing the 
data extraction, we found it more effective that two persons extracted data independently 
into the extraction forms, and afterwards we compared results. 
2. In the protocol, we wrote : “In case of very rare events (<1%) we will calculate Peto OR. 
Whenever appropriate, estimates will be pooled across trials in meta-analysis by using 
random effect models in the RevMan Software.” We used Peto OR and RR in accordance 
with the protocol, but Peto OR was used in combination with a fixed effect model rather than 
a random effect model. This is in accordance with recommendations for meta-analysis of 
rare events in the Cochrane Handbook.  
3. In the protocol, we defined three main endpoints: 1) Operative deliveries for fetal distress 2) 
Metabolic acidosis in the newborn and 3) Apgar score <4 and 7 at five minutes. During the 
process, we observed that only Belfort et al reported Apgar score <4 at 5 min and therefore 
decided to use 1) and 2) as primary endpoints. 
4. In the protocol, we wrote: “We will do subgroup analyses for old vs. new STAN technology.
” We had extensive discussions in the author group about doing subgroup analyses or not 
after we had collected the results from the included trials. Two of the included studies 
differed from the other four:  the Westgate trial used old technology without computerized 
assessment for the fetal ECG and the Belfort trial used a different decision algorithm. As our 
aim was to assess the efficacy of STAN in clinical settings, and we believe that the observed 
variation in settings is as close as can be expected to normal variations in practice, we 
included al six RCTs in the main analyses. We decided to do sensitivity analyses instead of 
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Supplementary file S3. Detailed risk of bias assessments 
Paper Amer-Wåhlin, Sweden 
(4, 25) 
Belfort, USA (14) Ojala, Finland (5) Vayssière, France (6) Westerhuis, The 
Netherlands (7, 26) 




Low risk of bias Low risk of bias Low risk of bias Low risk of bias Low risk of bias Low risk of bias 
Allocation 
concealment 




Not possible Not possible Not possible Not possible Not possible Not possible 
Blinding of 
outcome assessor 




Low risk of bias Low risk of bias Low risk of bias Low risk of bias Low risk of bias Low risk of bias 
Free of selective 
reporting 
Low risk of bias Low risk of bias Low risk of bias Low risk of bias Low risk of bias Low risk of bias 
Free of other 
bias* 
Low risk of bias Low risk of bias Low risk of bias Low risk of bias Low risk of bias Low risk of bias 
Total quality 
judgement 
Low risk of bias Low risk of bias Low risk of bias Low risk of bias Low risk of bias Low risk of bias 
 
 









CTG   
 Events/total 
 
Events/total  95% CI 
Metaboloc acidosis (cord pH < 7.05 + BD(ecf) >12mmol/l Peto OR, fixed effect  
Amer-Wåhlin1 (4) 18/2565 35/2484 0.51 (0.29-0.87) 
Belfort2 (14) 3/5532 8/5576 0.41 (0.12-1.32) 
Ojala3 (5) 6/714 4/722 1.51 (0.44-5.24) 
Vayssière (6) 8/399 5/400 1.60 (0.54. 4.79) 
Westerhuis4 (7) 19/2827 27/2840 0.71 (0.40-1.26) 
Westgate (3) 5/1219 13/1215 0.41 (0.16-1.03) 
Total 59/13256 92/13237 0.64 (0.46-0.88) 
Test for heterogeneity: I2=27% 
 
   
Sensitivity analysis. Westgate (3) not included:   
Total 54/12037 79/12022 0.68 (0.48-0.95) 
Test for heterogeneity: I2=31% 
 
   
Sensitivity analysis. Belfort (14) not included:   
Total 56/7724 84/7661 0.66 (0.47-0.92) 
Test for heterogeneity: I2=36% 
 
   
Total operative deliveries5 for fetal distress RR, random effect  
Amer-Wåhlin (4) 193/2519 227/2447 0.83 (0.69-0.99) 
Belfort (14) 512/5532 516/5576 1.00 (0.89-1.12) 
Ojala (5) 51/733 63/739 0.82 (0.57-1.16) 
Vayssière (6) 134/399 148/400 0.91 (0.75-1.10) 
Westerhuis (7) 261/2827 237/2840 1.11 (0.94-1.31) 
Westgate (3) 61/1219 111/1215 0.55 (0.40-0.74) 
Total 1212/13229 1302/13217 0.88 (0.75-1.03) 
Test for heterogeneity: I2=74% 
 
   
Sensitivity analysis. Westgate (3) not included:   
Total 1151/12010 1191/12002 0.95 (0.86-1.06) 
Test for heterogeneity: I2=42%    
Sensitivity analysis. Belfort (14) not included   
Total 700/7697 786/7641 0.84 (0.68-1.03) 
Test for heterogeneity: I2=77%    
Perinatal and neonatal death  Peto OR, fixed effect  
Amer-Wåhlin (4) 3/2519 2/2447 1.45 (0.25-8.38) 
Belfort (14) 3/5532 1/5576 2.74 (0.39-19.46) 
Ojala (5) 0/733 0/739 -  
Vayssière (6) 0/399 1/400 0.14 (0.00-6.84) 
Westerhuis (7) 3/2827 2/2840 1.50 (0.26-8.66) 
Westgate (3) 2/1219 0/1215 7.37 (0.46-117.91) 
Total 11/13229 6/13217 1.93 (0.62-5.98) 
Sensitivity analysis. Westgate (3) not included:   
Total 9/12010 6/12002 1.48 (0.54-4.08) 
Test for heterogeneity: I2=0% 
 
   
Sensitivity analysis. Belfort (14) not included:   
Total 8/7697 4/7641 1.57 (0.53-4.66) 
Test for heterogeneity: I2=0% 
 
   
Perinatal death   Peto OR, fixed effect  
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Amer-Wåhlin (4) 3/2519 2/2447 1.45 (0.25-8.38) 
Ojala (5) 0/733 0/739 - - 
Westerhuis (7) 3/2827 2/2840 1.50 (0.26-8.66) 
Westgate (3) 2/1219 0/1215 7.37 (0.62.5.98) 
Total 8/7298 4/7241 1.93 (0.62-5.98) 
Test for heterogeneity: I2=0% 
 
   
Sensitivity analysis. Westgate (3) not included:   
Total 6/6079 4/6026 1.47 (0.43-5.09) 
Test for heterogeneity: I2=0% 
 
   
Neonatal death   Peto OR, fixed effect  
Belfort (14) 3/5532 1/5576 2.74 (0.39-19.46) 
Vayssière (6) 0/399 1/400 0.14 (0-6.84) 
Total 3/5931 2/5976 1.50 (0.26-8.67) 
Test for heterogeneity: I2=45% 
 
   
Neonatal seizures   Peto OR, fixed effect  
Belfort (14) 3/5532 4/5576 0.76 (0.17-3.33) 
Ojala (5) 0/714 2/722 0.14 (0.01-2.19) 
Vayssière (6) 1/399 1/400 1.00 (0.06-16.06) 
Total 4/6645 7/6698 0.58 (0.18-1.90) 
Test for heterogeneity: I2=0% 
 
   
Sensitivity analysis. Belfort (14) not included:   
Total 1/1113 3/1122 0.37 (0.05-2.63) 
Test for heterogeneity: I2=0% 
 
   
Apgar score <4 at 5 min  Peto OR, fixed effect  
Belfort (14) 
 
17/5532 6/5576 2.86 (1.13-7.24) 
Apgar score <7 at 5 min  RR, random effect  
Amer-Wåhlin (4) 26/2519 28/2447 0.90 (0.53-1.53) 
Ojala (5) 9/714 8/722 1.14 (0.44-2.93) 
Vayssière (6) 6/399 6/400 1.00 (0.33-3.08) 
Westerhuis (7) 42/2827 34/2840 1.24 (0.79-1.94) 
Westgate (3) 20/1219 32/1215 0.62 (0.36-1.08) 
Total 103/7678 108/7624 0.95 (0.72-1.24) 
Test for heterogeneity: I2=0%    
Sensitivity analysis. Westgate (3) not included:   
Total 83/6459 76/6409 1.09 (0.80-1.48) 
Test for heterogeneity: I2=0% 
 
   
Neonatal encephalopathy  Peto OR, fixed effect  
Amer-Wåhlin (4) 3/2519 8/2447 0.39 (0.12-1.28) 
Belfort (14) 4/5532 5/5576 0.81 (0.22-2.98) 
Ojala (5) 0/714 1/722 0.14 (0-6.90) 
Westerhuis (7) 3/2827 1/2840 2.73 (0.38-19.41) 
Total 10/11592 15/11585 0.66 (0.30-1.46) 
Test for heterogeneity: I2=14% 
 
   
Sensitivity analysis. Belfort (14) not included:   
Total 6/6060 10/6009 0.60 (0.22-1.59) 
Test for heterogeneity: I2=40% 
 
   
Neonatal intubation   Peto OR, fixed effect  
Belfort (14) 42/5532 27/5576 1.56 (0.97-2.51) 
Ojala (5) 7/714 9/722 0.79 (0.29-2.10) 
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Total 49/6246 36/6298 1.37 (0.90-2.10) 
Test for heterogeneity: I2=34% 
 
   
Fetal blood sampling   RR, random effect  
Amer-Wåhlin (4) 234/2519 261/2447 0.87 (0.74-1.03) 
Ojala (5) 51/733 115/739 0.45 (0.33-0.61) 
Vayssière (6) 108/399 248/400 0.44 (0.37-0.52) 
Westerhuis (7) 301/2827 578/2840 0.52 (0.46-0.60) 
Westgate (3) 93/1219 114/1215 0.81 (0.63-1.06) 
Total 787/7697 1316/7641 0.59 (0.45-0.79) 
Test for heterogeneity: I2=91% 
 
   
Sensitivity analysis. Westgate (3) not included:   
Total 694/6478 1202/6426 0.55 (0.40-0.76) 
Test for heterogeneity: I2=92% 
 
   
Admittance to NICU RR, random effect  
Amer-Wåhlin (4) 169/2519 181/2447 0.91 (0.74-1.11) 
Belfort (14) 498/5532 470/5576 1.07 (0.95-1.20) 
Ojala (5) 26/714 26/722 1.01 (0.59-1.72) 
Vayssière (6) 5/399 6/400 0.84 (0.26-2.72) 
Westerhuis6 (7) 40/2827 45/2840 0.89 (0.59-1.36) 
Westgate (3) 24/1219 31/1215 0.77 (0.46-1.31) 
Total 767/13210 759/13200 1.00 (0.91-1.11) 
Test for heterogeneity: I2=0% 
 
   
Sensitivity analysis. Westgate (3) not included: RR, random effect  
Total 738/11991 728/11985 1.01 (0.92-1.12) 
Test for heterogeneity: I2=0% 
 
   
Sensitivity analysis. Belfort (14) not included:   
Total 264/7678 289/7624 0.90 (0.76-1.06) 
Test for heterogeneity: I2=0% 
 
   
Cord pH <7.05   RR, random effect  
Ojala (5) 20/714 8/722 2.53 (1.12-5.70) 
Vayssière (6) 12/399 11/400 1.09 (0.49-2.45) 
Westerhuis (7) 47/2827 70/2840 0.67 (0.47-0.97) 
Westgate (3) 23/1219 25/1215 0.92 (0.63-1.76) 
Total 102/5159 114/5177 1.05 (0.63-1.76) 
Test for heterogeneity: I2=66% 
 
   
Sensitivity analysis. Westgate (3) not included   
Total 76/3940 89/3962 1.16 (0.53-2.55) 
Test for heterogeneity. I2=77% 
 
   
Composite endpoint7   Peto OR, fixed effect  
Belfort (14) 
 
52/5532 40/5576 1.31 (0.87-1.98) 
Total operative deliveries5 for all indications RR, random effect  
Amer-Wåhlin (4) 454/2519 500/2447 0.88 (0.79-0.99) 
Belfort (14) 1263/5532 1228/5576 1.04 (0.97-1.11) 
Ojala (5) 117/733 114/739 1.03 (0.82-1.31) 
Vayssière (6) 216/399 221/400 0.98 (0.86-1.11) 
Westerhuis (7) 789/2827 822/2840 0.96 (0.89-1.05) 
Westgate (3) 344/1219 383/1215 0.90 (0.79-1.01) 
Total 3183/13229 3268/13217 0.96 (0.91-1.02) 




Sensitivity analysis. Westgate (3) not included:   
Total 2839/12010 2885/12002 0.98 (0.92-1.04) 
Test for heterogeneity: I2=35% 
 
   
Sensitivity analysis. Belfort (14) not included:   
Total 1920/7697 2040/7641 0.94 (0.89-0.99) 
Test for heterogeneity: I2=0%    
    
Cesarean delivery for fetal distress  RR, random effect  
Amer-Wåhlin (4) 87/2519 97/2447 0.87 (0.66-1.16) 
Belfort (14) 287/5532 298/5576 0.97 (0.83-1.14) 
Ojala (5) 15/733 15/739 1.01 (0.50-2.05) 
Vayssière (6) 54/399 65/400 0.83 (0.60-1.16) 
Westerhuis (7) 91/2827 70/2840 1.31 (0.96-1.78) 
Westgate (3) 15/1219 30/1215 0.50 (0.27-0.92) 
Total 549/13229 575/13217 0.93 (0.78-1.12) 
Test for heterogeneity: I2=47% 
 
   
Sensitivity analysis. Westgate (3) not included:   
Total 534/12010 545/12002 0.98 (0.85-1.13) 
Test for heterogeneity: I2=19% 
 
   
Sensitivity analysis. Belfort (14) not included:   
Total: 262/7697 277/2641 0.90 (0.69-1.19) 
Test for heterogeneity: I2=57% 
 
   
Cesarean delivery for all indications  RR, random effect  
Amer-Wåhlin (4) 210/2519 222/2447 0.92 (0.77-1.10) 
Belfort (14) 934/5532 901/5576 1.04 (0.96-1.14) 
Ojala (5) 47/733 35/739 1.35 (0.88-2.07) 
Vayssière (6) 99/399 109/400 0.91 (0.72-1.15) 
Westerhuis (7) 405/2827 391/2840 1.04 (0.91-1.18) 
Westgate (3) 115/1219 121/1215 0.95 (0.74-1.21) 
Total 1810/13229 1779/13217 1.02 (0.96-1.08) 
Test for heterogeneity: I2=0% 
 
   
Sensitivity analysis. Westgate (3) not included:   
Total 76/3940 89/3962 1.16 (0.53-2.55) 
Test for heterogeneity: I2=7% 
 
   
Sensitivity analysis. Belfort (14) not included:   
Total: 876/7697 878/7641 0.99 (0.91-1.08) 
Test for heterogeneity: I2=0% 
 
   
Operative vaginal delivery for fetal distress RR, random effect  
Amer-Wåhlin (4) 106/2519 130/2447 0.79 (0.62-1.02) 
Belfort (14) 255/5532 218/5576 1.04 (0.87-1.25) 
Ojala (5) 36/733 48/739 0.76 (0.50-1.15) 
Vayssière (6) 80/399 83/400 0.97 (0.73-1.27) 
Westerhuis (7) 170/2827 167/2940 1.06 (0.86-1.30) 
Westgate (3) 46/1219 81/1215 0.57 (0.40-0.81) 
Total 663/13229 727/13217 0.87 (0.74-1.03) 
Test for heterogeneity: I2=59% 
 
   
Sensitivity analysis. Westgate (3) not included:   
Total 617/12010 646/12002 0.95 (0.85-1.07) 




Sensitivity analysis. Belfort (14) not included:   
Total 438/7697 509/7641 0.83 (0.68-1.01) 
Test for heterogeneity: I2=58% 
 
   
Operative vaginal delivery for all indications RR, random effect  
Amer-Wåhlin (4) 244/2519 278/2447 0.85 (0.72-1.00) 
Belfort (14) 329/5532 327/5576 1.01 (0.87-1.18) 
Ojala (5) 70/733 79/739 0.89 (0.66-1.21) 
Vayssière (6) 117/399 112/400 1.05 (0.84-1.30) 
Westerhuis (7) 384/2827 431/2840 0.90 (0.79-1.02) 
Westgate (3) 229/1219 262/1215 0.87 (0.74-1.02) 
Total 1373/13229 1489/13217 0.92 (0.86-0.99) 
Test for heterogeneity: I2=0% 
 
   
Sensitivity analysis. Westgate (3) not included:   
Total 1147/1210 1227/12002 0.93 (0.86-1.00) 
Test for heterogeneity: I2=0% 
 
   
Sensitivity analysis. Belfort (14) not included:   
Total: 1044/7697 1162/7641 0.90 (0.83-0.97) 
Test for heterogeneity: I2=0% 
 
   
1We used corrected data published by Amer-Wåhlin et al. 2011 (25). 
2Belfort et al. (14) defined metabolic acidosis as pH < 7.05 and BD > 12.0, the other studies as pH < 7.05 and 
BD > 12.0. 
3Ojala et al. (5) used data with BD (blood), these have been recalculated to BD(ecf) and published by Welin et al 
(27). We used the recalculated data in the meta-analysis. 
4We used corrected data published by Westerhuis et al. 2011 (26). 
5Total operative deliveries = cesarean sections + operative vaginal deliveries. 
6We used corrected data published by Westerhuis et al. 2011 (26). 
7A composite of intrapartum death, neonatal death, Apgar score < 4 at 5 minutes, neonatal seizures, metabolic 





Supplementary S5: Trial sequential analysis (TSA) 
All trials are associated with a risk of arriving at erroneous conclusion. There is a risk of false positive 
findings (Type I errors), but there is also a risk that a trial erroneously arrive at negative conclusions 
(Type II errors). A reduction of the risk of type I and/or type II errors in a trial comes at the cost of a 
need to recruit more participants. Statistical power calculations are about finding an acceptable 
balance between the risk of arriving at erroneous conclusions and the need to limit the number of 
participants.  
Meta-analyses are also associated with certain risks of spurious findings due to type I and type II 
errors, but the pooled effect estimate can be expected to converge towards the truth as the number 
of available trials and the number of events accumulate. TSA can be used to evaluate if a meta-
analysis is prone to spurious findings, or whether the pooled estimate is likely to represent the truth. 
TSA calculation resembles traditional power analysis, and enquires the user to define a set of input 
variable, i.e. an estimate for baseline incidence, an estimate for minimal important difference, a limit 
for the largest acceptable risk of type I error, and a limit for the largest acceptable risk of type II 
errors.  
All TSA were conducted post hoc in TSA viewer (Version 0.9 beta. Copenhagen: Copenhagen Trial 
Unit, 2011). We used the same statistical methods in the TSA as in the main analysis in RevMan. Alfa-
spending boundaries were calculated using two-sided tests with accepted risks of type I and type II 
errors at 5% and 20%, respectively. An estimate for baseline incidence was obtained by calculating 




Incidence of metabolic acidosis 
Six included trials. The blue line shows the cumulative Z-score of the meta-analysis. The outer red 
line represents the alfa-spending level of significance, and the black dotted lines represents the 
conventional significance 5% significance borders. The inner red lines represent borders for non-




Meta-analysis      Boundaries 
Effect measure: peto odds ratio    Name: Alpha-spending 
Effect model: Fixed effect     Type: Two-sided 
Pooled effect: 0.64 (95% CI 0.46 to 0.88)    Type I error: 5% 
Heterogeneity (Q), p-value: 0.23    Power: 80% 
Inconsistency (I2): 27% (95% CI 0.00 to 0.53%)  Minimal important difference: RRR 50% 
 Diversity (D2): 36%     Incidence in control arm: 0.7% 
 
        Name: Conventional 
        Type: Two-sided 




Operative deliveries for fetal distress (cesarean sections, vacuum or forceps) 
Six included trials. The blue line shows the cumulative Z-score of the meta-analysis. The outer red 
line represents the alfa-spending level of significance, and the black dotted lines represents the 
conventional significance 5% significance borders. The inner red lines represent borders for non-




Meta-analysis      Boundaries 
Effect measure: Risk ratio     Name: Alpha-spending 
Effect model: Random effect (DL)    Type: Two-sided 
Pooled effect: 0.88 (95% CI 0.75 to 1.03)    Type I error: 5% 
Heterogeneity (Q), p-value: 0.002    Power: 80% 
Inconsistency (I2): 74% (95% CI 61 to 83%)   Minimal important difference: RRR 20% 
 Diversity (D2): 79%     Incidence in control arm: 10% 
 
        Name: Conventional 
        Type: Two-sided 




Incidence of neonatal or perinatal death 
Six included trials. The blue line shows the cumulative Z-score of the meta-analysis. The outer red 
line represents the alfa-spending level of significance, and the black dotted lines represents the 
conventional significance 5% significance borders. The inner red lines represent borders for non-




Meta-analysis      Boundaries 
Effect measure: peto odds ratio    Name: Alpha-spending 
Effect model: Fixed effect     Type: Two-sided 
Pooled effect: 1.79 (95% CI 0.69 to 4.63)    Type I error: 5% 
Heterogeneity (Q), p-value: 0.57    Power: 80% 
Inconsistency (I2): 0% (95% CI 0.00 to 0.54%)  Minimal important difference: RRR 50% 
 Diversity (D2): 0%     Incidence in control arm: 0.08% 
 
        Name: Conventional 
        Type: Two-sided 




Incidence of neonatal seizures 
Three included trials. The blue line shows the cumulative Z-score of the meta-analysis. The outer red 
line represents the alfa-spending level of significance, and the black dotted lines represents the 
conventional significance 5% significance borders. The inner red lines represent borders for non-




Meta-analysis      Boundaries 
Effect measure: peto odds ratio    Name: Alpha-spending 
Effect model: Fixed effect     Type: Two-sided 
Pooled effect: 0.59 (95% CI 0.18 to 1.90)    Type I error: 5% 
Heterogeneity (Q), p-value: 0.66    Power: 80% 
Inconsistency (I2): 0% (95% CI 0.00 to 0.60%)  Minimal important difference: RRR 50% 
 Diversity (D2): 0%     Incidence in control arm: 0.1% 
 
        Name: Conventional 
        Type: Two-sided 




Incidence of Apgar scores less than seven after five minutes 
Four included trials. The blue line shows the cumulative Z-score of the meta-analysis. The outer red 
line represents the alfa-spending level of significance, and the black dotted lines represents the 
conventional significance 5% significance borders. The inner red lines represent borders for non-




Meta-analysis      Boundaries 
Effect measure: Risk ratio     Name: Alpha-spending 
Effect model: Random effect (DL)    Type: Two-sided 
Pooled effect: 0.95 (95% CI 0.73 to 1.25)    Type I error: 5% 
Heterogeneity (Q), p-value: 0.44    Power: 80% 
Inconsistency (I2): 0% (95% CI 0.00 to 0.54%)  Minimal important difference: RRR 30% 
 Diversity (D2): 0%     Incidence in control arm: 1.4% 
 
        Name: Conventional 
        Type: Two-sided 
        Type I error: 5% 
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